IT IS CLAIMED:

A liposome composition, comprising:
a lipid having the formula

$$z$$
 $\bigcap_{n}L$ \bigcap_{O} \bigcap_{R^2} R^1

where each of R¹ and R² is an alkyl or alkenyl chain having between 8-24 carbon atoms, and each of R¹ and R² are independently selected:

n = 0-20, preferably n = 1-20;

L is selected from the group consisting of (i) -X-(C=O)-Y-, (ii) -X-(C=O)-, and (iii) -X-, where X and Y are independently selected from oxygen, NH and a direct bond;

Z is a weakly basic moiety that has a pK of less than 7.4 and greater than about 4.0.

- 2. The composition of claim 1, wherein X is NH and Y is oxygen.
- 3. The composition of claim 1, wherein L is a carbamate linkage, an ester linkage or a carbonate linkage.
 - 4. The composition of claim 1, wherein L is NH-(C=O)-O-.
 - 5. The composition of claim 1, wherein Z is an imidazole.
 - 6. The composition of claim 1, comprising between 1-80 mole percent of the lipid.
- 7. The composition of claim 1, wherein Z is a moiety having a pK value between 5.0-6.5.

- 8. The composition of claim 1, wherein each of R¹ and R² is an unbranched alkyl or alkenyl chain having between 8-24 carbon atoms.
 - 9. The composition of claim 8, wherein each of R¹ and R² is C₁₇H₃₅.
 - 10. The composition of claim 1, wherein n is between 1-10.
- 11. The composition of claim 1, further including a therapeutic compound entrapped in the liposomes.
 - 12. The composition of claim 11, wherein the therapeutic agent is a nucleic acid.
- 13. The composition of claim 12, wherein the nucleic acid is selected from DNA, RNA, fragments thereof and oligonucleotides.
- 14. The composition of claim 1, further including a ligand for targeting the liposomes to a target site.
- 15. The composition of claim 14, wherein the ligand is one having binding affinity for endothelial tumor cells and which is internalized by such cells.
- 16. The composition of claim 15, wherein the ligand is selected from the group consisting of E-selectin, Her-2 and FGF.
- 17. The composition of claim 1, wherein said liposomes further include between 5-20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer chain.
- 18. The composition of claim 17, wherein said hydrophilic polymer chain is polyethyleneglycol.

19. A lipid having the formula:

$$z$$
 R^1

where each of R¹ and R² is an alkyl or alkenyl chain having between 8-24 carbon atoms, and each of R¹ and R² are independently selected;

n = 0-20, preferably n = 1-20;

L is selected from the group consisting of (i) -X-(C=O)-Y-, (ii) -X-(C=O)-, and (iii) -X-, where X and Y are independently selected from oxygen, NH and a direct bond;

Z is a weakly basic moiety that has a pK of less than 7.4 and greater than about 4.0.

- 20. The lipid of claim 19, wherein X is NH and Y is oxygen.
- 21. The lipid of claim 19, wherein L is a carbamate linkage, an ester linkage or a carbonate linkage.
 - 22. The lipid of claim 19, wherein L is NH-(C=O)-O-.
 - 23. The lipid of claim 22, wherein Z is an imidazole.
- 24. The lipid of claim 19, wherein Z is a moiety having a pK value between 5.0-6.5.
- 25. The lipid of claim 19, wherein each of R¹ and R² is an unbranched alkyl or alkenyl chain having between 8-24 carbon atoms.
 - 26. The lipid of claim 23, wherein each of R1 and R2 is C17H35.
 - 27. The lipid of claim 19, wherein n is between 1-10.

- 28. A liposome comprising the lipid according to claim 19.
- 29. A liposome comprising the lipid according to claim 26.
- 30. A method for delivery of a therapeutic agent to the cytoplasm of a cell, comprising

preparing liposomes comprising a lipid having the formula

where each of R¹ and R² is an alkyl or alkenyl chain having between 8-24 carbon atoms, and each of R¹ and R² are independently selected;

n = 0-20, preferably n = 1-20;

L is selected from the group consisting of (i) -X-(C=O)-Y-, (ii) -X-(C=O)-, and (iii) -X-, where X and Y are independently selected from oxygen, NH and a direct bond;

Z is a weakly basic moiety that has a pK of less than 7.4 and greater than about 4.0; and

administering the liposomes to a subject.

- 31. The method of claim 30, wherein said preparing includes entrapping in the liposomes a nucleic acid.
 - 32. The method of claim 31, wherein the nucleic acid is an oligonucleotide.
- 33. The method of claim 30, wherein said preparing includes entrapping in the liposomes a protein.